Methotrexate

As a classic basic drug in the fields of rheumatism immunity and tumor therapy, methotrexate is a folate reductase inhibitor. It can block the DNA synthesis of tumor cells by inhibiting dihydrofolate reductase, and regulate immune inflammatory pathways at the same time. It is an anchor drug for the first-line treatment of rheumatoid arthritis, and is also widely used in the treatment of acute lymphoblastic leukemia, choriocarcinoma, psoriasis and other diseases, covering multiple groups of adult and pediatric patients. It has a clinical application history of more than 60 years, and is still the preferred basic drug recommended by multiple disease guidelines up to now.

At present, the global market size of methotrexate API is about USD 280 million, with a compound annual growth rate of 4.2% in the past 3 years, highlighting its rigid demand. China is the core supplier of methotrexate API in the world, with production capacity accounting for more than 70% of the global total. The top 3 enterprises account for 85% of the domestic market share, and multiple varieties have passed FDA and EU CEP certifications, with supply covering more than 40 countries and regions around the world. With the increase of diagnosis and treatment penetration rate of rheumatoid arthritis at the primary level and the implementation of the security policy for childhood leukemia, the growth rate of domestic market demand in the past two years is higher than the global average, reaching 6.1%.

CATO can provide a full set of impurity reference standards for methotrexate API. All products meet the requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and are in sufficient stock for direct delivery, which can fully meet the full-process needs of pharmaceutical enterprises in drug R&D, quality research and daily production quality inspection, and help cooperative customers quickly get through the compliance path.